As of 2026-10-06, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 15.9x | 15.3x |
| Forward P/E multiples | 17.0x - 19.1x | 18.0x |
| Fair Price | (53.38) - (49.81) | (52.39) |
| Upside | -232.2% - -223.3% | -229.7% |
| Date | EV/EBITDA |